“The second quarter of 2023 proved to be a highly beneficial time at Marker from an operational and clinical standpoint, and I am excited by our comprehensive strategic advancements,” commented Dr. Juan F. Vera
"In exchange for certain cell manufacturing assets, Cell Ready provided Marker with approximately $19 million in cash and Cell Ready will absorb approximately $11 million of Marker’s overhead expense annually while simultaneously ensuring that Marker’s manufacturing and research and development (R&D) needs will be fully met."
"we are finalizing an updated clinical development plan, which we expect to unveil in the coming months,” concluded Dr. Vera.
I wonder if the updated clinical development plan, which we expect to unveil in the coming months, is the stategic review due July/August?
19 million cash plus 11 million saved per year = value of 30 million for 2024 and 41 million for 2025?
AI
Market Data 
Markets 
